연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
2745. Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer
Sera Oh 1, Hobin Yang 2, Ho Rim Oh 1, Myeung-Ryun Seo 3, Chul-Hee Lee 4, Young-Hwa Kim 5, Jun Young Choi 6, Na Young Kim 6, Gi Jeong Cheon 5, Keon Wook Kang 7, Young Kee Shin 8, Hyewon Youn 9
Nucl Med Biol. 2022 Nov-Dec;114-115:135-142
Link
2744. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs
Park E, Lee C, Park J, Liu J, Hong J, Shin DY, Byun JM, Yun H, Koh Y, Yoon SS
Leuk Lymphoma. 2022 Nov 4:1-12
Link
2743. Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
Park H, Byun JM, Yoon SS, Koh Y, Yoon SW, Shin DY, Hong J, Kim I
PLoS One. 2022 Jan 27;17(1):e0260113
Link
2742. Expansion of Human Megakaryocyte-Lineage Progeny via Aryl Hydrocarbon Receptor Antagonism with CH223191
Kim D, Shin DY, Liu J, Jeong NR, Koh Y, Hong J, Huang X, Broxmeyer HE, Yoon SS
Stem Cell Rev Rep. 2022 Dec;18(8):2982-2994
Link
2741. The importance of critically short telomere in myelodysplastic syndrome
Shin DY, Lim KM, Park HS, Kwon S, Yoon SS, Lee DS
Biomark Res. 2022 Nov 10;10(1):79
Link
2740. Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
Lee C, Lee S, Park E, Hong J, Shin DY, Byun JM, Yun H, Koh Y, Yoon SS
Genome Med. 2022 Sep 28;14(1):111
Link
2739. Effect of Postoperative Radiotherapy for Patients with Differentiated Thyroid Cancer
Ryu H, Wu HG, Lee KE, Chung EJ, Ahn SH, Park YJ, Choi HS
Clin Endocrinol (Oxf). 2022 Dec 19. doi: 10.1111/cen.14865. Online ahead of print
Link
2738. Reducing target volume in definitive radiotherapy for human papillomavirus-associated tonsil cancer
Lee HI, Kim JH, Lee JH, Wu HG
Head Neck 2022 Apr;44(4):989-997
Link
2737. A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers
Kyoung-Seok Oh 1, Ah-Rong Nam 1, Ju-Hee Bang 1, Hye-Rim Seo 1 2, Jae-Min Kim 1 2, Jeesun Yoon 3, Tae-Yong Kim 1 3, Do-Youn Oh 4 5 6
Oncogene. 2022 Aug;41(32):3939-3952. doi: 10.1038/s41388-022-02384-w. Epub 2022 Jul 7.
Link
2736. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
Do-Youn Oh 1, Kyung-Hun Lee 2, Dae-Won Lee 3, Jeesun Yoon 3, Tae-Yong Kim 2, Ju-Hee Bang 4, Ah-Rong Nam 4, Kyoung-Seok Oh 4, Jae-Min Kim 5, Young Lee 6, Violeta Guthrie 6, Patricia McCoon 6, Weimin Li 6, Song Wu 6, Qu Zhang 6, Marlon C Rebelatto 6, Jin Won Kim 7
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532.
Link